https://www.pulmonem.ca/en/?page_id=10 2024-11-12T19:40:59+00:00 https://www.pulmonem.ca/fr/communique-de-presse/new-covid-19-drug-therapy-developed-by-canadian-biotech-start-up-headed-for-phase-iii-clinical-trial-sponsored-by-the-ri-muhc/ 2020-09-02T16:09:00+00:00 https://www.pulmonem.ca/wp-content/uploads/2020/09/pulmonem.jpg https://www.pulmonem.ca/en/media/Reformulated%20and%20patented%20version%20of%20well-known%20generic%20drug%20could%20prove%20to%20be%20a%20quick,%20safe%20and%20cost-effective%20way%20to%20accelerate%20recovery%20and%20prevent%20hospitalizations.#new_tab 2020-09-03T20:42:00+00:00 https://www.pulmonem.ca/wp-content/uploads/2020/09/nm-logo-4.png https://www.pulmonem.ca/wp-content/uploads/2021/02/27-jan-2021-Research-team-struggles-to-find-public-funds-for-low.docx.pdf#new_tab 2021-01-27T21:49:00+00:00 https://www.pulmonem.ca/wp-content/uploads/2021/02/Untitled-design.jpg https://www.pulmonem.ca/fr/communique-de-presse/promising-covid-19-therapeutic-drug-to-start-phase-3-clinical-trial-in-the-united-states/ 2021-11-22T19:53:57+00:00 https://www.pulmonem.ca/wp-content/uploads/2020/09/pulmonem.jpg https://www.pulmonem.ca/en/news-release/promising-covid-19-therapeutic-drug-to-start-phase-3-clinical-trial-in-the-united-states/ 2021-11-24T20:01:54+00:00 https://www.pulmonem.ca/wp-content/uploads/2020/09/pulmonem.jpg https://www.pulmonem.ca/wp-content/uploads/2021/02/27-jan-2021-Research-team-struggles-to-find-public-funds-for-low.docx.pdf#new_tab 2021-11-24T21:50:19+00:00 https://www.pulmonem.ca/wp-content/uploads/2021/02/Untitled-design.jpg https://www.pulmonem.ca/en/media/Reformulated%20and%20patented%20version%20of%20well-known%20generic%20drug%20could%20prove%20to%20be%20a%20quick,%20safe%20and%20cost-effective%20way%20to%20accelerate%20recovery%20and%20prevent%20hospitalizations.#new_tab 2021-11-25T20:47:11+00:00 https://www.pulmonem.ca/wp-content/uploads/2020/09/nm-logo-4.png https://www.pulmonem.ca/en/news-release/new-covid-19-drug-therapy-developed-by-canadian-biotech-start-up-headed-for-phase-iii-clinical-trial-sponsored-by-the-ri-muhc/ 2021-11-26T17:29:59+00:00 https://www.pulmonem.ca/wp-content/uploads/2020/09/pulmonem.jpg https://www.pulmonem.ca/en/news-release/old-drug-new-therapy-ri-muhc-sponsored-phase-iii-clinical-trial-ready-to-test-repurposed-dapsone-to-tone-down-lung-inflammation-caused-by-covid-19/ 2021-11-26T17:56:35+00:00 https://www.pulmonem.ca/wp-content/uploads/2020/09/RI.jpg https://www.pulmonem.ca/wp-content/uploads/2021/11/McGill_University_Health_Centre_Old_drug__new_therapy__RI_MUHC_s.jpg https://www.pulmonem.ca/fr/communique-de-presse/ancien-medicament-nouvelle-therapie-lessai-clinique-de-phase-iii-parraine-par-lir-cusm-pret-a-tester-une-nouvelle-version-de-la-dapsone-dans-le-but-dattenuer-linflammation-pulmonaire-causee/ 2021-11-29T15:43:43+00:00 https://www.pulmonem.ca/wp-content/uploads/2020/09/RI.jpg https://www.pulmonem.ca/wp-content/uploads/2021/11/McGill_University_Health_Centre_Old_drug__new_therapy__RI_MUHC_s.jpg